Moonlight Vista Sees Potential In Wowo (JMU); Revance Therapeutics (RVNC) Slips Into Negative Zone


Shares of Wowo Ltd. (Nasdaq:JMU) climbed more than 5% in after-hours trading Monday as the company said that Xiao Nan Guo Restaurants Holdings Ltd.’s subsidiary Moonlight Vista Ltd. will acquire a 9.82% stake in the Chinese B2B online e-commerce platform operator for about $47.5 million (HK$368,396,837)

JMU stock finished the regular session at $3.91, down $0.44 (or -10.11%) with a total volume of 5,876 shares traded.

Wowo, which provides integrated services to suppliers and customers in the catering industry in China trough its online e-commerce platform, has 665.46M Shares Outstanding, Market Capitalization (intraday) of $322.18M and JMU stock 52-week range is from $3.11 to $10.16 per share



Revance Therapeutics, Inc. (Nasdaq:RVNC) shares slumped over 20% to touch a new 52-week low in the extended session Monday after the company said that a late-stage trial evaluating its DaxibotulinumtoxinA Topical Gel (RT001) in patients with lateral canthal lines – or crow’s feet – has failed to meet the co-primary and other endpoints.

RVNC stock closed in negative territory by 0.60% (or -$0.11) at $18.35 and 683,708 of its shares changed hands during the day, increased activity versus its average volume (3m) of 237,970

Revance Therapeutics, which focuses on the development, manufacture, and commercialization of novel botulinum toxin products, has 28.47M Shares Outstanding. At close on Monday, the biotechnology company had a Market Capitalization of $522.37M and RVNC stock one-year range was between $15.41 and $42.41 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at